Granahan Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

Granahan Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.89M	Buy	1,305,177 +421,936	+48%	+$2.5M	0.32%	74
2026 Q1	$3.95M	Buy	883,241 +179,270	+25%	+$834K	0.19%	117
2025 Q4	$3.87M	Sell	703,971 -412,658	-37%	-$2M	0.17%	126
2025 Q3	$3.65M	Buy	1,116,629 +158,136	+16%	+$448K	0.15%	113
2025 Q2	$2.21M	Sell	958,493 -682,300	-42%	-$1.48M	0.09%	132
2025 Q1	$2.28M	Buy	1,640,793 +4,412	+0.3%	+$7.38K	0.11%	132
2024 Q4	$2.83M	Buy	1,636,381 +496,482	+44%	+$1.03M	0.12%	138
2024 Q3	$2.29M	Buy	1,139,899 +330,208	+41%	+$725K	0.09%	164
2024 Q2	$1.81M	Buy	+809,691	New	+$2.36M	0.07%	160

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Granahan Investment Management's TSHA Position: Q2 2026 in Review

Granahan Investment Management increased its Taysha Gene Therapies (TSHA) stake by 48% in Q2 2026, buying an estimated $2.5M and bringing the position to 1,305,177 shares worth $8.89M. The position accounts for 0.32% of the portfolio, ranked #74.

Granahan Investment Management first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Granahan Investment Management held 1,305,177 shares of Taysha Gene Therapies worth $8.89M as of Q2 2026.
Granahan Investment Management bought 421,936 Taysha Gene Therapies shares in Q2 2026, an estimated $2.5M.
Taysha Gene Therapies made up 0.32% of Granahan Investment Management's portfolio in Q2 2026, its #74 holding.
Granahan Investment Management first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.